Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy(Regeneron Pharmaceutical)

N/A

Report date: 2024/06/24 20:00:45

Base Information

Drug NameMucin-16 (MUC16) Protein Targeting Immune Cell Therapy(Regeneron Pharmaceutical)

Drug Alias NameMucin-16 (MUC16) Protein Targeting Immune Cell Therapy(Regeneron Pharmaceutical)Anti-MUC16 CAR T Cell Drug Product (Regeneron Pharmaceutical)27T5127T-51

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsMucin-16 modulators

TargetsMucin-16

Therapy Area/IndicationsFallopian Tube NeoplasmsPeritoneal NeoplasmsCarcinoma, Ovarian Epithelial

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesRegeneron Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesRegeneron Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsFallopian Tube NeoplasmsPeritoneal NeoplasmsCarcinoma, Ovarian Epithelial

Inactive IndicationsN/A

Other Information

ATC CodeN/A